Low Mass Blood Peptides Discriminative of Inflammatory Bowel Disease (IBD) Severity: A Quantitative Proteomic Perspective
Open Access
- 1 January 2016
- journal article
- research article
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 15 (1) , 256-265
Abstract
No abstract availableKeywords
This publication has 67 references indexed in Scilit:
- Analytical characterization and clinical evaluation of an enzyme-linked immunosorbent assay for measurement of afamin in human plasmaClinica Chimica Acta, 2013
- Combined Serological, Genetic, and Inflammatory Markers Differentiate Non-IBD, Crohnʼs Disease, and Ulcerative Colitis PatientsInflammatory Bowel Diseases, 2013
- The Proteomics Identifications (PRIDE) database and associated tools: status in 2013Nucleic Acids Research, 2012
- A Role for Serglycin Proteoglycan in Mast Cell Apoptosis Induced by a Secretory Granule-mediated PathwayJournal of Biological Chemistry, 2011
- Gut hormones: emerging role in immune activation and inflammationClinical and Experimental Immunology, 2010
- Skyline: an open source document editor for creating and analyzing targeted proteomics experimentsBioinformatics, 2010
- Bikunin Loss in Urine as Useful Marker for Bladder CarcinomaJournal of Urology, 2010
- Two Chromogranin A-Derived Peptides Induce Calcium Entry in Human Neutrophils by Calmodulin-Regulated Calcium Independent Phospholipase A2PLOS ONE, 2009
- Serglycin proteoglycan is required for secretory granule integrity in mucosal mast cellsBiochemical Journal, 2007
- Statistical significance for genomewide studiesProceedings of the National Academy of Sciences, 2003